Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100-Reference-Cited by-同舟云学术

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100

Published:2020-02-28 Issue:4 Volume:111 Page:1324-1332
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Nishio Shin¹^ORCID,Matsumoto Koji²,Takehara Kazuhiro³,Kawamura Naoki⁴,Hasegawa Kosei⁵,Takeshima Nobuhiro⁶,Aoki Daisuke⁷,Kamiura Shoji⁸,Arakawa Atsushi⁹,Kondo Eiji¹⁰,Hirakawa Tomoko¹¹,Yamamoto Keiko¹²,Aoki Masayuki¹²^ORCID,Stein Karen¹³,Keefe Stephen¹³,Fujiwara Keiichi⁵,Ushijima Kimio¹

Affiliation:

1. Kurume University School of Medicine Kurume Japan

2. Hyogo Cancer Center Akashi Japan

3. National Hospital Organization Shikoku Cancer Center Matsuyama Japan

4. Osaka City General Hospital Osaka Japan

5. Saitama Medical University International Medical Center Hidaka Japan

6. Cancer Institute Hospital of JFCR Tokyo Japan

7. Keio University Hospital Tokyo Japan

8. Osaka International Cancer Institute Osaka Japan

9. Nagoya City University Hospital Nagoya Japan

10. Mie University Hospital Tsu Japan

11. Oita University Hospital Yufu Japan

12. MSD K.K. Tokyo Japan

13. Merck & Co., Inc. Kenilworth NJ USA

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14340

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer Registry and Statistics.Cancer Information Service National Cancer Center Japan 2019.https://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed June 22 2019.

3. Ovarian cancer

4. Ovarian cancer

5. Second-Line Treatment of Ovarian Cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Limitations and potential of immunotherapy in ovarian cancer;Frontiers in Immunology;2024-01-09

2. Adverse Effect of the Duration of Antibiotic Use Prior to Immune Checkpoint Inhibitors on the Overall Survival of Patients with Recurrent Gynecologic Malignancies;Cancers;2023-12-07

3. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer;Biochemical Pharmacology;2023-09

4. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions;Cancer and Metastasis Reviews;2023-06-27

5. Advances in the application of immune checkpoint inhibitors in gynecological tumors;International Immunopharmacology;2023-04